BioSight
Companies
Korro Bio, Inc. logo

KRRO

NASDAQCAMBRIDGE, MA
Korro Bio, Inc.

Korro Bio develops oligonucleotide-based therapeutics, which are short strands of genetic material designed to treat disease by modifying gene expression. Following its November 2023 business combination with Frequency Therapeutics, Korro Bio is advancing multiple oligonucleotide lead candidates toward clinical development, though the specific therapeutic areas are not detailed in this excerpt. The organization is in the preclinical and early clinical development stage, with oligonucleotide candidates nominated or being evaluated for advancement into human testing.

Price history not yet available for KRRO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar